Registries in Immune Thrombocytopenia: The History of the Intercontinental Cooperative ITP Study Group

Chapter

Abstract

Primary immune thrombocytopenia (ITP) is an autoimmune-mediated bleeding disorder with unknown etiology and without a homogenous pathomechanism occurring in children and adults. Premature platelet destruction, inadequate platelet production, and platelet dysfunction of various degrees contribute to bleeding. The methods with which ITP was investigated evolved from descriptions of patients and series at a time when platelets were not yet identified to clinical randomized trials and sophisticated basic research. ITP is an orphan disease and therefore the clinical and pathophysiological investigations are difficult and expensive. Registries are ideal tools to overcome some of these problems and are appropriate preparers of clinical trials, as they allow the establishment of powerful international networks and represent structured databases with the potential to collect demographic, clinical, and laboratory data from a big number of patients. Registries are suited to follow-up patients and investigate the natural history of diseases. However there are also limitations, which are discussed in this review article. The Intercontinental Cooperative ITP Study Group (ICIS) started its registries in 1997 and studied the natural history of ITP in children and adults, including anamnestic, clinical, and laboratory data, but also efficacy and side effects of drugs and splenectomy. Although many successes have occurred during the last centuries, many problems await solutions, such as the predictability of severe bleeding and of the form of ITP.

Keywords

Immune thrombocytopenia Platelets Registry 

Notes

Acknowledgments

The author thanks the numerous ICIS investigators and their patients for providing their data and for their ongoing support. Many thanks go to Paul Imbach for his invitation to write this article and for his help. I thank Caroline Martin Asal, Verena Stahel, and Monika Imbach of the ICIS office in Basel, Switzerland, for their patience and help and all members of the ICIS Board for their continuous support of our group.

References

  1. Arnold DM. Bleeding complications in immune thrombocytopenia. Hematol Am Soc Hematol Educ Program. 2015;2015:237–42.Google Scholar
  2. Aslam R, et al. The spleen dictates platelet destruction, anti-platelet antibody production, and lymphocyte distribution patterns in a murine model of immune thrombocytopenia. Exp Hematol. 2017.  https://doi.org/10.1016/j.exphem.2016.07.004.
  3. Bolton-Maggs P. Severe bleeding in idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol. 2003;25(Suppl 1):S47–51.CrossRefPubMedGoogle Scholar
  4. Bolton-Maggs PH, Moon I. Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines. Lancet. 1997;350:620–3.CrossRefPubMedGoogle Scholar
  5. Chotsampancharoen T, et al. Predictive factors for resolution of childhood immune thrombocytopenia: experience from a single tertiary center in Thailand. Pediatr Blood Cancer. 2017;64:128–34.CrossRefPubMedGoogle Scholar
  6. George JN, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88:3–40.PubMedGoogle Scholar
  7. Glanz J, et al. A population-based, multisite cohort study of the predictors of chronic idiopathic thrombocytopenic purpura in children. Pediatrics. 2008;121:e506–12.CrossRefPubMedGoogle Scholar
  8. Gliklich R, et al., editors. Registries for evaluating patient outcomes: a user’s guide. Third edition. Two volumes. (Prepared by the outcome DEcIDE Center [Outcome Sciences, Inc., a Quintiles company] under contract no. 290 2005 00351 TO7.) AHRQ Publication No. 13(14)-EHC111. Rockville, MD: Agency for Healthcare Research and Quality; 2014. http://www.effectivehealthcare.ahrq.gov/registries-guide-3.cfm Google Scholar
  9. Guyatt GH, et al. Grades of recommendation for antithrombotic agents: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133(6 Suppl):123S–31S.CrossRefPubMedGoogle Scholar
  10. Haverman L, et al. Paediatric health-related quality of life: what is it and why should we measure it? Arch Dis Child. 2017.  https://doi.org/10.1136/archdischild-2015-310068.
  11. Heitink-Pollé KMJ, et al. Clinical and laboratory predictors of chronic immune thrombocytopenia in children: a systematic review and meta-analysis. Blood. 2014;124:3295–307.CrossRefPubMedGoogle Scholar
  12. Imbach P, et al. Historical aspects and present knowledge of idiopathic thrombocytopenic purpura. Br J Haematol. 2002;119:894–900.CrossRefPubMedGoogle Scholar
  13. Imbach P, et al., Guest editors. Intercontinental childhood ITP Study Group (ICIS): state-of-the-art expert meeting on ITP, September 23–25, 2003 – Buergenstock, Switzerland. J Pediatr Hematol Oncol. 2003;25(Suppl 1):1–84.Google Scholar
  14. Imbach P, et al. Childhood ITP: 12 months follow-up data from the prospective registry I of the Intercontinental Childhood ITP Study Group (ICIS). Pediatr Blood Cancer. 2006;46:351–6.CrossRefPubMedGoogle Scholar
  15. Kaznelson P. Verschwinden der hämorrhagischen Diathese bei einem Falle von essentieller Thrombopenie (Frank) nach Milzexstirpation. Wien Klin Wochenschr. 1916;29:1451–4.Google Scholar
  16. Kistanguri G, McCrae KR. Immune thrombocytopenia. Hematol/Oncol Clin N Am. 2013;27:495–520.CrossRefGoogle Scholar
  17. Kojouri K, et al. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood. 2004;104:2623–34.CrossRefPubMedGoogle Scholar
  18. Kühne T. Update on the Intercontinental Cooperative ITP Study Group (ICIS) and on the pediatric and adult registry on chronic ITP (PARC ITP). Pediatr Blood Cancer. 2013;60(Suppl 1):S15–8.CrossRefPubMedGoogle Scholar
  19. Kühne T. Diagnosis and management of immune thrombocytopenia in childhood. Hamostaseologie. 2017;37:36–44.CrossRefPubMedGoogle Scholar
  20. Kühne T, Imbach P, Guest editors. 2nd Intercontinental Childhood ITP Study Group (ICIS) expert meeting on “critical issues and future research of ITP”, September 16–18, 2006, Yverdon, Switzerland. Special issue 2006. Pediatr Blood Cancer. 2006;47:649–745.Google Scholar
  21. Kühne T, Imbach P, Guest editors. 3rd Intercontinental cooperative ITP Study Group (ICIS) expert meeting on consensus and development of strategies in ITP. Basel, Switzerland, September 3–5, 2009. Ann Hematol. 2010;89(Suppl 1):1–109.Google Scholar
  22. Kühne T, Imbach P, Guest editors. 4th Intercontinental cooperative ITP Study Group (ICIS) expert meeting on “changes in ITP of children and adults”, Montreux, Switzerland, September 13–15, 2012. Semin Hematol. 2013;50(Suppl 1):S1–S126.Google Scholar
  23. Kühne T, Imbach P, Guest editors. 5th Intercontinental cooperative ITP Study Group (ICIS) expert meeting on “immunomodulation and management in ITP and other autoimmune disorders”, Flüeli-Ranft, Switzerland, September 24–26, 2015. Semin Hematol. 2016;53(Suppl 1):S1–S72.Google Scholar
  24. Kühne T, Schifferli A. On behalf of the Intercontinental Cooperative ITP Study Group (ICIS). A comparative prospective observational study of children and adults with immune thrombocytopenia: 2-year follow-up. 58th ASH annual meeting. Abstract. Blood. 2016;128(22):3741.Google Scholar
  25. Kühne T, et al. Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. Lancet. 2001;358:2122–5.CrossRefPubMedGoogle Scholar
  26. Kühne T, et al. A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group. J Pediatr. 2003;143:605–8.CrossRefPubMedGoogle Scholar
  27. Kühne T, et al. Splenectomy in children with idiopathic thrombocytopenic purpura: a prospective study of 134 children from the Intercontinental Childhood ITP Study Group. Pediatr Blood Cancer. 2007;49:829–34.CrossRefPubMedGoogle Scholar
  28. Kühne T, et al. Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group. Haematologica. 2011;96:1831–7.CrossRefPubMedPubMedCentralGoogle Scholar
  29. Michel M, et al. Characteristics and outcome of immune thrombocytopenia in elderly: results from a single center case-controlled study. Am J Hematol. 2011;86:980–4.CrossRefPubMedGoogle Scholar
  30. Moulis G, et al. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood. 2014;124:3308–15.CrossRefPubMedGoogle Scholar
  31. Neunert CE, et al. Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood. 2008;112:4003–8.CrossRefPubMedPubMedCentralGoogle Scholar
  32. Neunert C, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117:4190–207.CrossRefPubMedGoogle Scholar
  33. Neunert CE, et al. Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS). Blood. 2013;121:4457–62.CrossRefPubMedGoogle Scholar
  34. Neunert C, et al. Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J Thromb Haemost. 2014;13:457–64.CrossRefGoogle Scholar
  35. Perera M, Garrido T. Advances in the pathophysiology of primary immune thrombocytopenia. Hematology. 2017;22:41–53.CrossRefPubMedGoogle Scholar
  36. Revel-Vilk S, et al. Age and duration of bleeding symptoms at diagnosis best predict resolution of childhood immune thrombocytopenia at 3, 6, and 12 months. J Pediatr. 2013;163:1335–9.CrossRefPubMedGoogle Scholar
  37. Rodeghiero F, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura (ITP) of adults and children. Report from an international working group. Blood. 2009;113:2386–93.CrossRefPubMedGoogle Scholar
  38. Rosthøj S, et al. Duration and morbidity of chronic immune thrombocytopenic purpura in children: five-year follow-up of a Nordic cohort. Acta Paediatr. 2012;101:761–6.CrossRefPubMedGoogle Scholar
  39. Ruggeri M, et al. Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: a critical appraisal from literature analysis. Pediatr Blood Cancer. 2006;47:653–6.CrossRefPubMedGoogle Scholar
  40. Schifferli A, Kühne T. Chronic immune thrombocytopenia in children: who needs splenectomy? Semin Hematol. 2013;50(Suppl 1):S58–62.CrossRefPubMedGoogle Scholar
  41. Stasi R. Immune thrombocytopenia: pathophysiologic and clinical update. Semin Thromb Hemost. 2012;38:454–62.CrossRefPubMedGoogle Scholar
  42. Tamminga R, et al. Possible lower rate of chronic ITP after IVIG for acute childhood ITP an analysis from registry I of the Intercontinental Cooperative ITP Study Group (ICIS). Br J Haematol. 2009;146:180–4.CrossRefPubMedGoogle Scholar
  43. Werlhof PG. De Variolis et Anthracibus. Hannover; 1735.Google Scholar
  44. Zeller B, et al. Childhood idiopathic thrombocytopenic purpura in the Nordic countries: epidemiology and predictors of chronic disease. Acta Paediatr. 2005;94:178–84.CrossRefPubMedGoogle Scholar
  45. Zufferey A, et al. Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP). J Clin Med. 2017;6(2):1–21.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Oncology/HematologyUniversity Children’s HospitalBaselSwitzerland

Personalised recommendations